{
    "organizations": [],
    "uuid": "3ef842543728e116bf1bd34673d816d16461c28f",
    "author": "",
    "url": "https://www.reuters.com/article/brief-ema-to-review-cemiplimab-as-potent/brief-ema-to-review-cemiplimab-as-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma-idUSFWN1RG013",
    "ord_in_thread": 0,
    "title": "BRIEF-‍EMA To Review Cemiplimab As Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - Regeneron Pharmaceuticals Inc:\n* ‍EMA TO REVIEW CEMIPLIMAB AS A POTENTIAL TREATMENT FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA​\n* ‍EUROPEAN MEDICINES AGENCY HAS ACCEPTED FOR REVIEW MARKETING AUTHORIZATION APPLICATION (MAA) FOR CEMIPLIMAB​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-03T08:04:00.000+03:00",
    "crawled": "2018-04-03T08:21:24.016+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "regeneron",
        "pharmaceutical",
        "inc",
        "review",
        "cemiplimab",
        "potential",
        "treatment",
        "advanced",
        "cutaneous",
        "squamous",
        "cell",
        "medicine",
        "agency",
        "accepted",
        "review",
        "marketing",
        "authorization",
        "application",
        "maa",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}